Brian Abrahams
Stock Analyst at RBC Capital
(1.39)
# 3,152
Out of 4,814 analysts
433
Total ratings
33.48%
Success rate
-12.79%
Average return
Main Sectors:
Stocks Rated by Brian Abrahams
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Upgrades: Outperform | $138 → $137 | $100.10 | +36.86% | 18 | Apr 14, 2025 | |
| BCRX BioCryst Pharmaceuticals | Reiterates: Outperform | $11 | $7.39 | +48.85% | 17 | Apr 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $408 → $420 | $489.10 | -14.13% | 51 | Apr 1, 2025 | |
| AARD Aardvark Therapeutics | Reiterates: Outperform | $21 | $6.92 | +203.47% | 2 | Apr 1, 2025 | |
| SRPT Sarepta Therapeutics | Downgrades: Sector Perform | $161 → $87 | $53.79 | +61.74% | 33 | Mar 31, 2025 | |
| MLTX MoonLake Immunotherapeutics | Initiates: Outperform | $67 | $37.90 | +76.78% | 1 | Mar 18, 2025 | |
| GHRS GH Research | Initiates: Outperform | $31 | $9.10 | +240.66% | 1 | Mar 7, 2025 | |
| PLRX Pliant Therapeutics | Maintains: Sector Perform | $4 → $3 | $1.46 | +105.48% | 13 | Mar 4, 2025 | |
| NMRA Neumora Therapeutics | Reiterates: Sector Perform | $4 | $0.65 | +518.43% | 6 | Mar 4, 2025 | |
| PRTA Prothena Corporation | Maintains: Sector Perform | $24 → $20 | $9.23 | +116.68% | 10 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $45 | $5.06 | +790.21% | 11 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $63 | $47.45 | +32.77% | 18 | Feb 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $231 → $225 | $118.61 | +89.70% | 34 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $84 → $90 | $104.53 | -13.90% | 31 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $70 → $68 | $58.22 | +16.80% | 20 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $139 → $143 | $104.43 | +36.93% | 2 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $40 | $16.32 | +145.10% | 1 | Jan 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $20 → $1.5 | $1.24 | +21.46% | 15 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $31 | $4.57 | +578.34% | 4 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $4 → $1.5 | $0.33 | +357.04% | 5 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $48 → $2 | $0.77 | +158.63% | 11 | Dec 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Perform | $4 | $7.44 | -46.20% | 21 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $1,260 → $1,215 | $563.16 | +115.75% | 30 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $32 → $30 | $24.72 | +21.38% | 11 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $82 | $6.04 | +1,257.62% | 7 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $55 | $35.16 | +56.45% | 13 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $13 → $12 | $6.07 | +97.86% | 14 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $22 | $5.77 | +281.28% | 9 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $25 → $15 | $5.13 | +192.40% | 14 | Oct 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $12 → $9 | $1.48 | +508.11% | 3 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $21 → $33 | $43.00 | -23.26% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $35.64 | - | 4 | Dec 4, 2017 |
Neurocrine Biosciences
Apr 14, 2025
Upgrades: Outperform
Price Target: $138 → $137
Current: $100.10
Upside: +36.86%
BioCryst Pharmaceuticals
Apr 11, 2025
Reiterates: Outperform
Price Target: $11
Current: $7.39
Upside: +48.85%
Vertex Pharmaceuticals
Apr 1, 2025
Maintains: Sector Perform
Price Target: $408 → $420
Current: $489.10
Upside: -14.13%
Aardvark Therapeutics
Apr 1, 2025
Reiterates: Outperform
Price Target: $21
Current: $6.92
Upside: +203.47%
Sarepta Therapeutics
Mar 31, 2025
Downgrades: Sector Perform
Price Target: $161 → $87
Current: $53.79
Upside: +61.74%
MoonLake Immunotherapeutics
Mar 18, 2025
Initiates: Outperform
Price Target: $67
Current: $37.90
Upside: +76.78%
GH Research
Mar 7, 2025
Initiates: Outperform
Price Target: $31
Current: $9.10
Upside: +240.66%
Pliant Therapeutics
Mar 4, 2025
Maintains: Sector Perform
Price Target: $4 → $3
Current: $1.46
Upside: +105.48%
Neumora Therapeutics
Mar 4, 2025
Reiterates: Sector Perform
Price Target: $4
Current: $0.65
Upside: +518.43%
Prothena Corporation
Feb 21, 2025
Maintains: Sector Perform
Price Target: $24 → $20
Current: $9.23
Upside: +116.68%
Feb 20, 2025
Reiterates: Outperform
Price Target: $45
Current: $5.06
Upside: +790.21%
Feb 18, 2025
Maintains: Outperform
Price Target: $60 → $63
Current: $47.45
Upside: +32.77%
Feb 13, 2025
Maintains: Outperform
Price Target: $231 → $225
Current: $118.61
Upside: +89.70%
Feb 12, 2025
Maintains: Sector Perform
Price Target: $84 → $90
Current: $104.53
Upside: -13.90%
Feb 11, 2025
Maintains: Sector Perform
Price Target: $70 → $68
Current: $58.22
Upside: +16.80%
Feb 3, 2025
Maintains: Outperform
Price Target: $139 → $143
Current: $104.43
Upside: +36.93%
Jan 28, 2025
Reiterates: Outperform
Price Target: $40
Current: $16.32
Upside: +145.10%
Jan 10, 2025
Downgrades: Sector Perform
Price Target: $20 → $1.5
Current: $1.24
Upside: +21.46%
Jan 9, 2025
Reiterates: Outperform
Price Target: $31
Current: $4.57
Upside: +578.34%
Dec 20, 2024
Maintains: Sector Perform
Price Target: $4 → $1.5
Current: $0.33
Upside: +357.04%
Dec 20, 2024
Downgrades: Sector Perform
Price Target: $48 → $2
Current: $0.77
Upside: +158.63%
Nov 21, 2024
Upgrades: Sector Perform
Price Target: $4
Current: $7.44
Upside: -46.20%
Nov 1, 2024
Maintains: Outperform
Price Target: $1,260 → $1,215
Current: $563.16
Upside: +115.75%
Nov 1, 2024
Maintains: Sector Perform
Price Target: $32 → $30
Current: $24.72
Upside: +21.38%
Sep 20, 2024
Reiterates: Outperform
Price Target: $82
Current: $6.04
Upside: +1,257.62%
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $35.16
Upside: +56.45%
Aug 6, 2024
Maintains: Sector Perform
Price Target: $13 → $12
Current: $6.07
Upside: +97.86%
Jun 5, 2024
Reiterates: Outperform
Price Target: $22
Current: $5.77
Upside: +281.28%
Oct 2, 2023
Maintains: Sector Perform
Price Target: $25 → $15
Current: $5.13
Upside: +192.40%
Mar 31, 2022
Maintains: Sector Perform
Price Target: $12 → $9
Current: $1.48
Upside: +508.11%
Nov 3, 2021
Maintains: Sector Perform
Price Target: $21 → $33
Current: $43.00
Upside: -23.26%
Dec 4, 2017
Upgrades: Buy
Price Target: n/a
Current: $35.64
Upside: -